Multiple sclerosis (MS) is a chronic disease of the central nervous system characterized by periods of relapse and remission of neurological symptoms and progression of disability over time. Although the etiology of MS is unknown, most researchers consider it to be an immune-mediated disease. Mitoxantrone, a DNA topoisomerase II inhibitor used in cancer therapy, was the first immunosuppressant agent to receive approval from the USA Food and Drug Administration and the European Union for treatment of worsening relapsing/remitting, secondary progressive and progressive-relapsing MS.
Therapy-related acute myeloid leukemia (t-AML) may occur in two forms: the first is preceded by a longer lasting myelodysplastic phase, it is associated with alkylating substances and or ionizing radiation and is related to unbalanced chromosomal abnormalities, including deletions of chromosome 5 or 7. The second form is characterized by a short latency, acute onset and cytogenetic changes similar to de novo leukemias (e.g., translocations involving 11q23 or 8;21 or 15;17) and is associated with the use of DNA topoisomerase II inhibitors (such as epipodophyllotoxins, anthracyclines, carboplatin and mitoxantrone). 1 Over the last few years, several reports have indicated that the incidence of t-AML in the population of MS patients treated with mitoxantrone is higher than the risk of de novo AML in the general population. The occurrence of acute promyelocytic leukemia (APL) in MS patients treated with mitoxantrone has been well documented (Table 1) . [2] [3] [4] [5] [6] We report two new cases of APL in MS patients following treatment with mitoxantrone.
The first patient, a 21-year-old woman with MS since 1999, started to suffer from progressive-relapsing disease in February 2001 and was treated with beta-interferon followed by 10 courses of mitoxantrone (12 mg/m 2 ; total dose 170 mg) from August 2002 to December 2003. A second course of betainterferon was started in March 2005 but had to be interrupted 3 months later for severe fatigue, profuse sweating, gum bleeding and general status worsening. Blood tests showed leukocytopenia (white blood cell (WBC) 1.19 Â 10 9 /l), anemia (hemoglobin 7.9 mg/dl) and thrombocytopenia (platelets 30 Â 10 9 /l). Physical examination revealed pallor, mild hepatosplenomegaly and petechiae. Bone marrow aspirate demonstrated a markedly hypercellular marrow with 80% blast cells containing Auer rods. Coagulation parameters were consistent with consumption coagulopathy.
Immunophenotyping identified the blast cells CD45 þ , CD13 þ , CD33 þ , CD34À and HLA-DRÀ. Cytogenetic evaluation showed 46XX,t(15;17)(q22;q12). PML/RAR-alpha fusion gene rearrangement was confirmed by fluorescence in situ hybridization and molecular analysis. A diagnosis of APL (FAB M3) was formulated. The patient was treated with all-trans retinoic acid (ATRA) 45 mg/m 2 for 30 days and intravenous Idarubicin at a dosage of 12 mg/m 2 on days 2, 4, 6 and 8 of the induction therapy according to the all-trans retinoic acid and Idarubicin (AIDA) protocol. 7 A bone marrow study performed on day þ 41 revealed normal tri-lineage hematopoiesis without evidence of residual leukemic cells. Subsequently, the patient underwent three cycles of consolidation treatment with ATRA (45 mg/m 2 /day) each starting from days 1 to 15 combined with Idarubicin (5 mg/m 2 ) on days 1-4. A repeat bone marrow study on day þ 120, after completion of the consolidation treatment, confirmed complete morphologic, cytogenetic and molecular remission.
In February 2006, the patient underwent autologous hematopoietic stem cell transplantation (HSCT) according to a multicenter experimental protocol, which included MS patients with documented rapidly progressive MS over the previous year despite immunomodulating or immunosuppressive treatments. The study was approved by the local ethics committee and the patient gave her written informed consent.
Peripheral blood stem cells were mobilized with cyclophosphamide and filgrastim. The conditioning therapy consisted of cyclophosphamide 60 mg/kg for 2 days followed by rabbit antithymocyte globulin (3.75 mg/kg/day at days þ 2 and þ 3).
Complete molecular remission was confirmed 6 months after transplantation.
The ). Physical examination revealed pallor and mild hepatomegaly. The bone marrow aspirate revealed 80% of hypergranular blasts containing Auer rods and immunophenotyping (CD45 þ , CD33 þ , CD13 þ , CD34À, HLA-DRÀ) led to the diagnosis of APL (FAB M3). Cytogenetic studies showed the classic translocation 15;17 (q22;q12) and molecular analysis confirmed the presence of the PML/RAR-alpha fusion gene. After induction and consolidation therapy as per the AIDA protocol, 7 a bone marrow aspirate on day þ 120 showed complete cytogenetic and molecular remission.
In July 2006, the patient underwent autologous HSCT according to the same experimental protocol of the first patient.
Little is still known about the pathogenetic mechanisms in t-AML that can lead to the chromosomal translocation t(15;17) and the PML/RAR-alpha fusion transcripts occurring in APL. A recent report suggests that mitoxantrone induces in vitro topoisomerase II-mediated cleavage of PML and RARA genes and that this cleavage could be a general mechanism causing the DNA damage that develops after treatment with drugs that target topoisomerase II.
Moreover, the genetic damage induced by chemotherapic drugs can result in clonal proliferation, which may be an essential early step in leukemogenesis, occurring before the development of clinical abnormalities. 8 It is not yet possible to quantify the risk of APL onset following mitoxantrone treatment in MS patients owing to the sporadic number of reported cases. In our cohort study, 250 MS patients were treated with mitoxantrone and only two patients (0.8%) developed APL. Nevertheless, these two further cases emphasize the need for doctors to carefully consider the choice of mitoxantrone for the treatment of MS and to include the potential risk of t-AML in each informed consent. It should also be considered that this secondary leukemia does not seem to be dose related and that onset latency may be variable. 8 Although the efficacy of mitoxantrone in severe MS has been well documented, patients treated with this drug require special vigillance and hematological evaluation for several years after discontinuation of therapy.
Intense immunosuppression followed by autologous HSCT is currently considered a possible therapeutic strategy for severe MS; the rationale for this procedure stems from the possibility to eradicate self-reactive immune cells by intensive immunosuppression and to achieve complete immune reconstitution by engraftment of autologous hematopoietic stem cells. 9 From our report, the question arises whether such transplant procedure may also be beneficial for MS patients affected by t-AML after topoisomerase II treatment. Binaghi', Cagliari, Italy and
